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Purpose of the study
Chronic invasive fungal sinusitis is a rare condition, and
the conventional treatment surgical debridement and
systemic antifungal therapy such as amphotericin B.
Recently, voriconazole has demonstrated superior effi-
cacy in the treatment of invasive aspergillosis, compared
to amphotericin B. However, its use in invasive fungal
sinusitis in an HIV patient has not been reported.
Methods
We describe a case of chronic invasive fungal sinusitis in
a patient with HIV infection successfully treated with
surgical clearance and a prolonged course of oral
voriconazole.
Summary of results
A 39 year old Malawian lady presented to the Ear,
Nose and Throat (ENT) surgeons with recurrent nasal
polyps and was noted to have proptosis in April 2009.
She had had a previous polypectomy in 2007, which
grew Streptococcal pyogenes and Aspergillus flavus.
MRI sinuses in May 2009 demonstrated extensive soft
tissue mass involving right maxillary, bilateral ethmoid
and frontal sinuses, causing right axial proptosis. Dural
enhancement suggested intracranial extension, and
there was erosion into pituitary fossa posteriorly. Her
only complaint was epiphora, with no visual distur-
bance. An HIV test was positive. Baseline CD4 count
was 395 cells/cm
3, and viral load 103,469 copies/ml.
She underwent endoscopic sinus surgery to debulk tis-
sue from her sinuses. Grocott staining of biopsy speci-
men demonstrated presence of fungal hyphae, and
tissue culture grew Aspergillus flavus.S h ew a sc o m -
menced on oral voriconazole 300mg b.d. Due to
potential drug interactions with non-nucleoside reverse
transcriptase inhibitors (NNRTI) and protease inhibi-
tors (PI), she was treated with tenofovir, emtricitabine
and raltegravir. Follow-up MRI after 4 months of ther-
apy showed marked improvement with resolution of
proptosis. She has been on voriconazole for 12 months
with no progression.
Conclusions
Invasive fungal sinusitis has been rarely reported in HIV
patients, but recent case reports in non-HIV immuno-
compromised patients have shown a favourable response
to new triazoles. It has previously been associated with
high mortality even with amphotericin therapy. There
are important potential interactions with antiretroviral
(ARV) drugs. The optimal duration of treatment for
immunocompromised patients is unclear.
Author details
1The Infection, Tropical Medicine and Counselling Service, Brownlee Centre,
Gartnavel General Hospital, Glasgow, UK.
2Glasgow Royal Infirmary,
Department of Ear, Nose and Throat, Glasgow, UK.
Published: 8 November 2010
doi:10.1186/1758-2652-13-S4-P190
Cite this article as: Ho et al.: Treatment of chronic invasive fungal
sinusitis with voriconazole in an HIV patient. Journal of the International
AIDS Society 2010 13(Suppl 4):P190.
1The Infection, Tropical Medicine and Counselling Service, Brownlee Centre,
Gartnavel General Hospital, Glasgow, UK
Full list of author information is available at the end of the article
Ho et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P190
http://www.jiasociety.org/content/13/S4/P190
© 2010 Peters et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.